On Tuesday, Neurocrine Biosciences, Inc. (NASDAQ: NBIX) opened higher 1.09% from the last session, before settling in for the closing price of $133.62. Price fluctuations for NBIX have ranged from $93.02 to $148.37 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 34.77% annually for the last half of the decade. Company’s average yearly earnings per share was noted 90.08% at the time writing. With a float of $98.41 million, this company’s outstanding shares have now reached $98.70 million.
In an organization with 1400 employees, it is important to assess its efficiency.
Neurocrine Biosciences, Inc. (NBIX) Insider Updates
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Neurocrine Biosciences, Inc. is 2.21%, while institutional ownership is 93.47%. The most recent insider transaction that took place on May 31 ’24, was worth 37,278. In this transaction Chief Regulatory Officer of this company sold 273 shares at a rate of $136.55, taking the stock ownership to the 7,507 shares. Before that another transaction happened on May 29 ’24, when Company’s Director sold 40,000 for $133.46, making the entire transaction worth $5,338,564. This insider now owns 26,504 shares in total.
Neurocrine Biosciences, Inc. (NBIX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 90.08% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.00% during the next five years compared to 62.04% growth over the previous five years of trading.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Trading Performance Indicators
Check out the current performance indicators for Neurocrine Biosciences, Inc. (NBIX). In the past quarter, the stock posted a quick ratio of 2.47. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.86. Likewise, its price to free cash flow for the trailing twelve months is 22.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.64, a number that is poised to hit 1.16 in the next quarter and is forecasted to reach 6.98 in one year’s time.
Technical Analysis of Neurocrine Biosciences, Inc. (NBIX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.18 million. That was better than the volume of 0.83 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 61.29%. Additionally, its Average True Range was 3.72.
During the past 100 days, Neurocrine Biosciences, Inc.’s (NBIX) raw stochastic average was set at 34.76%, which indicates a significant decrease from 69.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 21.35% in the past 14 days, which was lower than the 27.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $137.03, while its 200-day Moving Average is $128.15. However, in the short run, Neurocrine Biosciences, Inc.’s stock first resistance to watch stands at $136.18. Second resistance stands at $137.28. The third major resistance level sits at $138.56. If the price goes on to break the first support level at $133.80, it is likely to go to the next support level at $132.52. Assuming the price breaks the second support level, the third support level stands at $131.42.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Key Stats
There are currently 100,637K shares outstanding in the company with a market cap of 13.59 billion. Presently, the company’s annual sales total 1,887 M according to its annual income of 249,700 K. Last quarter, the company’s sales amounted to 515,300 K and its income totaled 43,400 K.
